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Synopsis 
 The glial cells of the brain and the peripheral nervous system retain the capacity 
to divide and proliferate throughout the lifespan of an individual and thereby have the 
propensity to give rise to the most adult neurological tumours. Among them, the tumours 
which arise from different kinds of glial cells are referred to as gliomas. Of the various 
types of gliomas, astrocytomas are the most common central nervous system neoplasms 
which make upto 60% of all the primary brain tumours. Being the most prevalent type, the 
WHO classifies them into grades ranging from I to IV based on their intensity of 
malignancy. Grade IV astrocytoma or Glioblastoma (GBM) is considered to be the most 
malignant form with a median survival of 14.6 months, in spite of all therapeutic 
modalities. GBM is further classified as primary and secondary GBM. Primary GBM 
manifests de novo without any early history of pre-malignant lesions, on the other hand 
secondary GBM arises progressively from lower grades over a period of 5-10 years.  
  Like other malignancies, GBM also arises from various genetic and epigenetic 
variations. Epigenetic variations include all such mitotically and meiotically heritable traits 
that do not involve changes in DNA sequence. There are three major areas of epigenetics - 
DNA methylation, histone modifications and non-coding RNAs which are known to have 
profound effects on gene expression. A lot being known about the genetic derailments in 
GBM, in this study we looked into the epigenetic aspects of GBM. In our lab, we have 
carried out various high throughput studies, which unveiled the distorted landscape of 
DNA methylation and miRNA expression in GBM. This indicates that, in addition to the 
genetic mechanisms of gene alterations like mutations, copy number aberrations, protein 
coding genes are also affected by changes in methylation as well as by miRNA 
misregulation. The study has been divided into two parts. Part one of the study deals with 
the identification of chromobox homolog 7 (Cbx7), as a hypermethylated and 
downregulated gene in GBM. More importantly, Cbx7 is a member of the polycomb 
repressive complex and brings about its function through chromatin modifications. Here 
we have investigated the role of Cbx7 in gliomagenesis, and why it has to be silenced by 
methylation for tumorigenesis to ensue. In part two, we elucidated two unique ways of 
miRNA regulation in GBM. In the first section, we identified miR-326 as a PI3 kinase 
regulated miRNA and demonstrated its tumour suppressive role in GBM. In the other 
section, we analysed the copy number aberration data from TCGA and identified miR-
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4484 as a miRNA subjected to deletion in GBM. We further went ahead to demonstrate its 
growth suppressive role in GBM. 
Part 1: Epigenetic regulation of the chromatin modifier Cbx7; 
chromobox homolog 7 
 DNA methylation is involved in the normal cellular control of expression and 
thereby plays a crucial role in maintaining the homeostasis of the cell. The phenomenon of 
DNA methylation keeps the various loci of the genome such as the germline specific genes 
and the repetitive transposable elements silenced, whereas the tumour suppressors and 
other growth modulator genes are spared from the methylation induced gene repression. 
One of the important steps that promote tumorigenesis is aberrant hypermethylation, which 
leads to the silencing of tumour-suppressor genes. Another important epigenetic 
phenomenon that affects the transcriptibility of the genome is histone modifications, which 
control the accessibility of the chromatin to the transcriptional machinery. In this section, 
we identified Cbx7, which happens to be an essential component of the chromatin 
modifying machinery, as an epigenetically regulated gene in GBM. We observed from the 
methylation array carried out in our lab, that Cbx7 was one of the highly methylated genes. 
We also validated that Cbx7 is downregulated in GBM and the same observation was 
further corroborated from other data sets. The hypermethylated state of Cbx7 was 
confirmed by DNA bisulphite sequencing and the expression levels of Cbx7 also got 
alleviated after 5-Aza-2′-deoxycytidine treatment, which is a DNA methylation inhibitor. 
This indicated that the down regulation of Cbx7 could be attributed to the methylation of 
its promoter region. In order to figure out the role of Cbx7 in GBM, we carried out 
transcriptome analysis of Cbx7 overexpressing cells compared to vector control condition 
by RNA sequencing. Gene ontology analysis revealed a significant enrichment of 
pathways involved in cell cycle, migration and invasion like processes. In fact, the 
exogenous overexpression of Cbx7 leads to cell death, reduced colony formation, retarded 
migration and invasion of cells. In order to explain the above phenotypes brought about by 
the exogenous expression of Cbx7, we further examined the RNA sequencing data and 
observed that many of the top most downregulated genes in Cbx7 overexpression state 
belonged to the Hippo signaling pathway. The effectors of the Hippo pathway, YAP and 
TAZ which essentially antagonize the pathway activity, are well known for their role in 
proliferation, migration and invasion in cancer. So we carried out a Gene Set Enrichment 
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Analysis (GSEA) and found that there was a significant negative enrichment of YAP/TAZ 
targets in the Cbx7 regulated gene set. We validated some of these targets that were 
downregulated by Cbx7 overexpression. One of the most downregulated genes that we 
validated was Connective Tissue Growth Factor (CTGF), which also happens to be a 
bonafide target of YAP/TAZ. Independent downregulation of CTGF also resulted in 
reduced migration, thereby phenocopying the effects as were produced by Cbx7 
overexpression. Moreover, we also observed that SAPK/JNK was the only kinase whose 
activity was abolished upon Cbx7 overexpression. Since CTGF is known to activate 
SAPK/JNK, we assessed the SAPK/JNK activity upon CTGF silencing. We found that 
levels of phospho-SAPK/JNK were significantly reduced in CTGF silenced condition. In 
addition to that, the inhibition of the SAPK/JNK by synthetic inhibitor also hampered the 
migration ability of the cells. We were also able to rescue the loss of migratory potential of 
glioma cells by the exogenous overexpression of CTGF in Cbx7 stable background. A 
similar rescue was also achieved by the overexpression of a constitutively active form of 
SAPK/JNK. This indicates that Cbx7 activates Hippo pathway to inhibit YAP/TAZ 
dependent transcription, resulting in the downregulation of CTGF, thereby inhibiting 
CTGF mediated activation of SAPK and thus resulting in the inhibition of glioma cell 
migration. 
PART 2: ROLE OF MIRNAS IN GLIOMA DEVELOPMENT AND 
PROGRESSION 
 miRNAs are a class of small non-coding RNAs that are not translated into 
functional proteins but still contribute to numerous cellular processes, thereby adding yet 
another realm of regulation and control. miRNAs bring about gene regulation at the post-
transcriptional level, either by degrading the mRNA or by translational repression and in 
this manner fine tune the expression of protein coding genes. miRNAs are often located in 
the  most fragile sites of the genome which exposes them to grave genetic alterations, thus 
providing a circumstantial evidence of their etiological role in tumorigenesis. In a 
malignant state, miRNAs have been found to play pivotal roles in cellular transformation 
by altering various cellular phenotypes. Owing to their participation in diverse cellular 
functions, miRNAs have gained a strong foothold in gene regulation. Though a lot has 
been deciphered about the functional aspect of miRNAs, not much is known about the 
precise mechanisms which lead to their misregulation and therefore demands in-depth 
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study. The expression of miRNAs can be modulated by a variety of genetic and epigenetic 
mechanisms. 
Section I: Role of miR-326 – a PI3 kinase regulated miRNA, in gliomagenesis 
 The TCGA group in the year 2008 identified three major pathways which go 
disarray in GBM. These include the pro-tumorigenic receptor tyrosine kinase (RTK) 
pathway, and the p53 and the pRB tumour-suppressive pathways. The RTK signalling 
includes the PI3 kinase pathway, which is pivotal in gliomagenesis and many other 
cancers. This directed us to elucidate the set of miRNAs which are controlled by the 
aberrant functioning of the PI3 kinase pathway. We used synthetic inhibitor LY294002 to 
abrogate the PI3 kinase signalling and examined the miRNA profile in two glioma cell 
lines U87 and U251, which have an activated PI3 kinase pathway.  Indeed the abrogation 
of the PI3 kinase pathway resulted in the modulation of a wide array of miRNAs. We 
validated miR-326 as one of the miRNAs that was upregulated upon PI3 kinase pathway 
abrogation. Furthermore, we observed that miR-326 was a down regulated miRNA in 
GBM and different glioma cell lines, as well as in many other publicly available data sets. 
We also observed that miR-326 is an intragenic miRNA and its host gene Arrestin β1 
(ARRB1) also exhibited similar upregulation upon PI3K pathway inhibition. Over-
expression of miR-326 resulted in various anti-tumorigenic affects like reduced 
proliferation, reduced migration and colony suppression. In order to find the targets of 
miR-326, we analysed the transcriptome by RNA sequencing upon pre-miR-326 
transfection. We shortlisted and validated some of the genes which were getting regulated 
through miRNA over-expression and also explain the functional role of miR-326. 
Section II: Role of miR-4484 – a copy number deleted miRNA, in gliomagenesis 
In the TCGA study mentioned above, it was also unfurled that there are many 
genes in the RTK, p53 and pRB signalling pathways which are made dysfunctional 
through gene deletions and amplifications. We envisaged whether it is only the protein 
coding genes which are subjected to such regulations or the non-coding genes like 
miRNAs as well. In this pursuit, we identified miR-4484 as one of the miRNAs located in 
the deleted region of uroporphyrinogen III synthase (UROS) gene in the chromosome 11 of 
the GBM genome. As conceived, miR-4484 was observed to be a downregulated miRNA 
in association with its host gene UROS. We further elucidated that the downregulation was 
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due to the co-deletion of a locus harbouring both the protein coding gene and the miRNA. 
In addition, upon over-expression of miR-4484, we observed reduced migration and colony 
formation, indicating its role as a tumour–suppressor. For seeking the targets of miR-4484, 
we extracted RNA from miR-4484 over-expression condition and subjected it to RNA 
sequencing. We shortlisted and validated some of the genes which were getting regulated 
through miRNA over-expression and possibly explain the functional role of miR-4484.  
 
 
 
 
 
 
